November 20, 2025

Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer data

IntelME Verdict

Strategic Shift

TL;DR

Metagenomi and Ovid Therapeutics undergo CEO transitions, with Metagenomi restructuring to prioritize gene-editing program, while Cogent Biosciences sees stock rise on promising stomach cancer data.

Analysis

The CEO transitions at Metagenomi and Ovid signal a strategic shift towards prioritizing key programs, like gene-editing for Metagenomi and leadership continuity for Ovid. Cogent Biosciences' stock rise indicates market confidence in their promising stomach cancer data, potentially positioning them as a strong player in the oncology space.

Source

BioPharma Dive↗